X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr. Reddys Quarterly Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dr. Reddys Quarterly Results   (REDY)

Here are the latest quarterly results of Dr. Reddys. For more details, see the Dr. Reddys financial fact sheet and Dr. Reddys share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

Dr. Reddys Quarterly Results

No. of Mths
Qtr. Ending
3
Jun-17
*
3
Sep-17
*
3
Dec-17
*
3
Mar-18
*
3
Jun-18
*
3
Sep-18
*
3
Dec-18
*
3
Mar-19
*
8-Qtr Chart
Click to enlarge
Net Sales Rs m33,33235,59838,34135,53937,36538,17538,64640,296 
Other income Rs m3803164304495041,2821,023833 
Turnover Rs m33,71235,91438,77135,98837,86939,45739,66941,129 
Expenses Rs m30,10028,90430,41429,90329,67730,58230,60032,107 
Gross profit Rs m3,3306,7867,9275,7057,7717,5938,0468,189 
Depreciation Rs m2,5922,7022,7152,7632,7872,7862,9032,872 
Interest Rs m215223172178195208241245 
Profit before tax Rs m9034,1775,4703,2135,2935,8815,9255,905 
Tax Rs m2371,1232,5284925328071,0111,508 
Profit after tax Rs m6663,0542,9422,7214,7615,0744,9144,397 
Gross profit margin %10.019.120.716.120.819.920.820.3 
Effective tax rate %26.226.946.215.310.113.717.125.5 
Net profit margin %2.08.67.77.712.713.312.710.9 
Diluted EPS Rs 4.0 18.4 17.8 16.4 28.7 30.6 29.7 26.5  
Diluted EPS (TTM) Rs 72.7 72.5 60.6 56.6 81.3 93.5 105.4 115.5  
 Subscriber Feature View View View            
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Read: Dr. Reddys 3QFY19 Result Performance Review

More Pharmaceuticals Company Quarterly Results:   FULFORD INDIA  DIVIS LABORATORIES  ALEMBIC PHARMA  J.B.CHEMICALS  ELDER PHARMA  

Compare DR. REDDYS LAB With:   FULFORD INDIA  DIVIS LABORATORIES  ALEMBIC PHARMA  J.B.CHEMICALS  ELDER PHARMA  

Compare DR. REDDYS LAB With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 71 Points Lower; Metal and Energy Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their volatile trading day marginally lower.

Views on news

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jun 24, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS